TrialPath
COPD · Boston

COPD clinical trials in Boston

20 recruiting chronic obstructive pulmonary disease studies within range of Boston. Click any trial for full eligibility criteria and contact info.

A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)

NCT07116031 · Chronic Graft Versus Host Disease
Recruiting

This is an open-label, single group, Phase 1/2, 1-arm study for treatment of children aged 1 to \<18 years with active moderate-to-severe cGVHD that is refractory to or recurred after at least 2 prior lines of systemic therapy for cGVHD. The purpose of Phase 1 is to determine the PK profiles and to establish the Recommended Pediatric Equivalent Dose (RPED) of belumosudil in participants aged 1 to \<12 years with active moderate to severe cGVHD. Upon completion and evaluation of Phase 1, Phase 2 will commence with the purpose of determining safety and efficacy (ORR by 24 weeks) of belumosudil in participants aged 1 to \<18 years. Study details include: The end of study is defined as 3 years after the last participant is recruited or all participants have discontinued treatment, or have died, whichever comes first. Minimum of 6 participants ages 1 to 6 years will be enrolled for each phase of study Individual participant duration on study will consist of: Up to 4 weeks for screening. Treatment until clinically significant progression of cGVHD, relapse/recurrence of the underlying disease, start of a new systemic treatment for cGVHD, experience of an unacceptable adverse event, request from participant or Investigator, or until the end of the study is reached, whichever comes first. 30 days of post treatment safety follow-up. Long-term follow-up until death or end of study, whichever occurs first.

PhasePhase 2
TypeInterventional
Age1 Year – 18 Years
WhereLos Angeles, California, United States + 34 more
SponsorSanofi
▾Tap for details
Apply

A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

NCT04710576 · Chronic Graft-versus-host-disease
Recruiting

This is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3 different dose levels in participants with recurrent or refractory active chronic graft versus host disease (cGVHD) who have received at least 2 prior lines of systemic therapy.

PhasePhase 2
TypeInterventional
Age2 Years
WhereBirmingham, Alabama, United States + 120 more
SponsorSyndax Pharmaceuticals
▾Tap for details
Apply

A Multi Center Study Testing a New Implant for Adults With Severe Emphysema

NCT07119229 · Emphysema or COPD, Emphysema, COPD
Recruiting

A study taking place at multiple sites in the United States, Europe and Brazil to evaluate how well a new therapy for severe COPD/emphysema works, and how safe it is.

PhaseNA
TypeInterventional
Age22 Years
WhereSan Francisco, California, United States + 3 more
SponsorPulmair Medical, Inc.
▾Tap for details
Apply

Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)

NCT06462365 · Hematologic Malignancy, GvHD, GVHD,Acute
Recruiting

The purpose of this Phase 1, first in human open-label study is to assess the safety and tolerability of TRX-103 in patients with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell transplantation (HSCT). It is anticipated that up to 36 Subjects will be enrolled during a 18-24 month enrollment period. TRX-103 will be infused one time post HSCT.

PhasePhase 1
TypeInterventional
Age18 Years
WhereDuarte, California, United States + 4 more
SponsorTr1X, Inc.
▾Tap for details
Apply

myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home

NCT05204888 · COPD
Recruiting

Parallel-group, prospective, randomized, controlled phase III trial of home High flow Nasal Therapy (HFNT) via myAirvo 3 plus usual COPD medical care vs. usual COPD medical care, for at least 1 year and up to two years in 642 GOLD Grade D, Stages II-IV patients with moderate to very severe COPD at risk for moderate and severe exacerbations with a prior history of severe exacerbation requiring hospitalization within the past 6 weeks.

PhaseNA
TypeInterventional
Age30 Years
WhereBirmingham, Alabama, United States + 26 more
SponsorTemple University
▾Tap for details
Apply

Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH

Recruiting

The investigators will study whether the drug tadalafil improves shortness of breath in 126 Veterans with Chronic Obstructive Pulmonary Disease (COPD) and high blood pressure in the lungs. The investigators will also assess whether tadalafil improves quality of life, home daily physical activity, exercise endurance, the frequency of acute flares of COPD, blood pressure in the lungs, and lung function. Veterans who enroll in the trial will be allocated by chance to either active tadalafil or an inactive identical capsule (placebo). Neither the Veteran nor the investigator will know whether the Veteran is taking tadalafil or placebo. Veterans will be followed closely in clinic or by telephone at 1, 2, 3, 4, 5, and 6 months, with attention to side effects and safety. At 1,3, and 6 months the investigators will repeat the questionnaires and testing of blood pressures in the lung and lung function. The investigators anticipate that the results of this study will determine whether tadalafil improves shortness of breath when added to usual medications for COPD.

PhasePhase 2
TypeInterventional
Age35 Years – 89 Years
WhereAurora, Colorado, United States + 4 more
SponsorVA Office of Research and Development
▾Tap for details
Apply

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

NCT06615050 · Graft-versus-host Disease (GVHD)
Recruiting

The purpose of this study is to assess Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation

PhasePhase 3
TypeInterventional
Age18 Years
WherePalo Alto, California, United States + 29 more
SponsorIncyte Corporation
▾Tap for details
Apply

Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease

NCT05919511 · cGVHD
Recruiting

The purpose of this prospective observational study is to collect data from participants who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of Chronic Graft Versus Host Disease(cGVHD)

Phase—
TypeObservational
Age18 Years
WhereBirmingham, Alabama, United States + 36 more
SponsorIncyte Corporation
▾Tap for details
Apply

Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease

NCT05996627 · Chronic Graft Versus Host Disease
Recruiting

This phase II trial compares the effect of belumosudil to a placebo in treating patients with chronic graft versus host disease. Chronic graft versus host disease remains a major complication of stem cell transplantation and can involve multiple organ systems. Belumosudil is a ROCK2 selective inhibitor that works to reduce the immune system response causing the chronic graft versus host disease. Giving belumosudil may better treat patients with chronic graft versus host disease and prevent the need for starting additional immune suppressive medications.

PhasePhase 2
TypeInterventional
Age18 Years
WhereDuarte, California, United States + 4 more
SponsorFred Hutchinson Cancer Center
▾Tap for details
Apply

Ex Vivo-Expanded Regulatory T Cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic GVHD

NCT06991361 · Graft Versus Host Disease (cGvHD)
Recruiting

Hematopoietic Stem Cell Transplant (HCT) has been used to treat children and adults who have leukemia, lymphoma and other cancers of blood and immune cells since the 1970s. For many of these forms of cancer, HCT works well. However, HCT can cause serious, sometimes life-threatening complications. One of the most serious and common complications of HCT is graft-versus-host disease (GVHD). GVHD can appear early after the transplant, usually about 3 to 4 weeks after the transplant is given. This is called acute GVHD (aGVHD), because it usually happens over a couple of days. If successfully treated, acute GVHD quickly goes away. Sometimes GVHD happens months after the transplant. Then it is called chronic GVHD (cGVHD), because it happens gradually and goes away slowly. The investigators are doing this study to see if one dose of Ex vivo-Expanded Regulatory T cells (EVE-Treg) can be used together with the daily Interleukin 2 (IL-2) to treat cGVHD, that has not responded to steroid treatment or low-dose IL-2.

PhasePhase 1
TypeInterventional
Age2 Years
WhereBoston, Massachusetts, United States
SponsorSarah Nikiforow, MD
▾Tap for details
Apply

BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

NCT05922761 · Bronchiolitis Obliterans Syndrome, Bronchiolitis Obliterans, Lung Diseases
Recruiting

The goal of this research study is to test the efficacy of a novel immunosuppressive agent, belumosudil, in allogeneic hematopoietic stem cell transplant (HSCT) recipients who have been newly diagnosed or have developing (early stage) bronchiolitis obliterans syndrome (BOS). The name of the study drugs involved in this study are: * Belumosudil (an immunotherapy) * Fluticasone (an intranasal corticosteroid) * Azithromycin (an antibiotic) * Montelukast (a leukotriene receptor antagonist) * Prednisone (a corticosteroid)

PhasePhase 2
TypeInterventional
Age18 Years
WhereStanford, California, United States + 5 more
SponsorDana-Farber Cancer Institute
▾Tap for details
Apply

Inter-lobar Fissure Completion in Patients With Failed Bronchoscopic Lung Volume Reduction

NCT05257681 · Emphysema or COPD
Recruiting

The purpose of this protocol is to perform a pilot prospective controlled clinical trial to evaluate the potential role of lung fissure completion with pleural adhesiolysis strategy (experimental intervention) in severe emphysema/COPD patients with failed bronchoscopic lung volume reduction (BLVR) via the use of endobronchial valves (EBVs) therapy. In select patients, the lung fissure completion with adhesiolysis strategy will be performed by video-assisted thoracoscopic surgery (VATS) guided stapling along the lung fissures to reduce collateral ventilation with adhesions removal and determine whether this experimental strategy will improve outcomes after failed BLVR in patients with severe emphysema/COPD.

PhaseNA
TypeInterventional
Age40 Years – 75 Years
WhereBoston, Massachusetts, United States
SponsorBeth Israel Deaconess Medical Center
▾Tap for details

Axatilimab for Sclerotic Chronic Graft-versus-Host Disease

NCT07011810 · Chronic Graft Versus Host Disease
Recruiting

This phase II trial tests how well axatilimab works in treating patients with thickening or hardening (sclerosis) of the skin related to chronic graft-versus-host disease after a donor stem cell transplant. Chronic graft-versus-host disease (cGVHD) remains a major complication of donor stem cell transplants. Sclerosis, while not associated with a higher risk of death, can lead to serious disabilities. Usual treatments for cGVHD can be associated with significant side effects and unsatisfactory outcomes. A monoclonal antibody, like axatilimab, is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Axatilimab blocks a receptor and depletes cells that may be involved in the development of inflammation and fibrosis in cGVHD. Giving axatilimab may improve or prevent worsening of sclerosis related to cGVHD in patients after a donor stem cell transplant.

PhasePhase 2
TypeInterventional
Age18 Years
WhereTampa, Florida, United States + 2 more
SponsorFred Hutchinson Cancer Center
▾Tap for details
Apply

The Effect of a Technology-Mediated Integrated Walking and Tai Chi Intervention on Physical Function in Veterans With COPD and Chronic Musculoskeletal Pain

NCT05701982 · COPD, Chronic Musculoskeletal Pain
Recruiting

Persons with COPD benefit from being physically active, but they are often limited by chronic musculoskeletal pain. This project will determine whether a non-pharmacologic, integrated, technology-mediated walking and Tai Chi mindfulness intervention can improve physical function in Veterans with COPD and chronic musculoskeletal pain. The proposed research addresses VA Rehabilitation R\&D Service's high priority area of improving health-related quality of life by reducing disease burden and maximizing function in Veterans with chronic disease.

PhaseNA
TypeInterventional
Age40 Years – 100 Years
WhereBoston, Massachusetts, United States
SponsorVA Office of Research and Development
▾Tap for details
Apply

An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema

NCT06035120 · Emphysema, Pulmonary, Emphysema or COPD
Recruiting

This is a prospective, open-label, multi-center, single-arm study planned to enroll 200 subjects with heterogeneous emphysema and collateral ventilation (CV) in the target lobe. Subjects will undergo instillation of AeriSeal Foam in the target lobe and subsequent assessment of CV status using Chartis Pulmonary Assessment System. Subjects with CV- status will then undergo placement of Zephyr Valve in the target lobe for bronchoscopic lung volume reduction (BLVR) and be followed for 24 months.

PhaseNA
TypeInterventional
Age40 Years – 80 Years
WherePhoenix, Arizona, United States + 37 more
SponsorPulmonx Corporation
▾Tap for details
Apply

Mindful Steps 2.0: Promoting Physical Activity in Patients With COPD and HF

Recruiting

The goal of this fully-remote randomized controlled trial is to test the efficacy of Mindful Steps in facilitating physical activity compared to usual standard of care among 136 patients with COPD and/or HF. The main question it aims to answer is can this intervention promote physical activity as measured by daily step counts in sedentary patients with COPD and/or HF. Participants will be randomized (1:1 ratio) to receive either the Mindful Steps intervention or usual care for 12 months, with both arms receiving a Walking for Health education booklet.

PhaseNA
TypeInterventional
Age40 Years
WhereBoston, Massachusetts, United States + 1 more
SponsorBeth Israel Deaconess Medical Center
▾Tap for details
Apply

STRIVE Post-Market Registry Study

NCT04302272 · Emphysema
Recruiting

This is a single-arm, prospective, multi-center, Registry study to evaluate the long-term safety and effectiveness of the Spiration Valve System (SVS) for the treatment of severe emphysema in a post-market setting.

Phase—
TypeObservational
Age18 Years
WherePhoenix, Arizona, United States + 15 more
SponsorOlympus Corporation of the Americas
▾Tap for details
Apply

Home Hospital for Suddenly Ill Adults

NCT03524222 · Infection, Heart Failure, COPD
Recruiting

The investigators propose a home hospital model of care that substitutes for treatment in an acute care hospital. Limited studies of the home hospital model have demonstrated that a sizeable proportion of acute care can be delivered in the home with equal quality and safety, reduced cost, and improved patient experience.

PhaseNA
TypeInterventional
Age18 Years
WhereBoston, Massachusetts, United States + 1 more
SponsorBrigham and Women's Hospital
▾Tap for details
Apply

Plasma and Radiologic Biomarkers of Response to ECP in Lung Transplant Recipients With CLAD

NCT07434869 · Lung Transplant Failure and Rejection, CLAD, Bronchiolitis Obliterans, Extracorporeal Photopheresis
Recruiting

This study is for people who have had a lung transplant and developed a condition called chronic lung allograft dysfunction (CLAD), which is a type of chronic rejection. Doctors often treat CLAD with a procedure called extracorporeal photopheresis (ECP), but it can take up to six months to know if the treatment is working. The goal of the study is to find early signs (biomarkers) that show whether ECP is helping, so patients can get the right care sooner. For participants in the study, small blood samples will be collected at three points during ECP treatment and, for some participants, two MRI scans of the lungs will be performed-one before starting ECP and one after finishing treatment. The MRI uses a safe contrast dye to help us see changes in lung blood flow and tissue. Investigators will also look at certain immune cells in the blood. This is not a study of a new drug or treatment-participants will receive the same ECP therapy their doctor already recommended. The study will help researchers understand how ECP works and identify markers that predict who benefits most. There is no direct benefit to participants, but participation may help improve care for future lung transplant patients.

Phase—
TypeObservational
Age7 Years
WhereBoston, Massachusetts, United States + 2 more
SponsorBrian Keller
▾Tap for details
Apply

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

Recruiting

This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.

PhasePhase 3
TypeInterventional
Age40 Years – 80 Years
WhereAthens, Alabama, United States + 921 more
SponsorAstraZeneca
▾Tap for details
Apply